Literature DB >> 30540342

Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics.

Gregory S Phillips1, Azael Freites-Martinez1,2, Jennifer Wu1,3,4, Donald Chan1, Gabriella Fabbrocini5, Matthew D Hellmann6, Mario E Lacouture1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30540342      PMCID： PMC6439535          DOI： 10.1001/jamadermatol.2018.4560

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  6 in total

1.  Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.

Authors:  Alice P Chen; Ann Setser; Milan J Anadkat; Jonathan Cotliar; Elise A Olsen; Benjamin C Garden; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2012-04-11       Impact factor: 11.527

2.  A pilot quality-of-life instrument for pruritus.

Authors:  Nisha S Desai; Gabriele B Poindexter; Yvette Miller Monthrope; Sandra E Bendeck; Robert A Swerlick; Suephy C Chen
Journal:  J Am Acad Dermatol       Date:  2008-06-11       Impact factor: 11.527

3.  Prevalence of chronic itch and associated factors in haemodialysis patients: a representative cross-sectional study.

Authors:  Melanie Weiss; Thomas Mettang; Ulrich Tschulena; Jutta Passlick-Deetjen; Elke Weisshaar
Journal:  Acta Derm Venereol       Date:  2015-09       Impact factor: 4.437

Review 4.  Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.

Authors:  Vincent Sibaud
Journal:  Am J Clin Dermatol       Date:  2018-06       Impact factor: 7.403

5.  The impact of pruritus on quality of life: the skin equivalent of pain.

Authors:  Seema P Kini; Laura K DeLong; Emir Veledar; Anne Marie McKenzie-Brown; Michael Schaufele; Suephy C Chen
Journal:  Arch Dermatol       Date:  2011-06-16

Review 6.  Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

Authors:  Shrujal Baxi; Annie Yang; Renee L Gennarelli; Niloufer Khan; Ziwei Wang; Lindsay Boyce; Deborah Korenstein
Journal:  BMJ       Date:  2018-03-14
  6 in total
  13 in total

1.  Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

Authors:  Mari Aso; Yukihiro Toi; Jun Sugisaka; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Takahiro Ogasawara; Kyoji Tsurumi; Kana Ono; Hisashi Shimizu; Yutaka Domeki; Keisuke Terayama; Yosuke Kawashima; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda; Shunichi Sugawara
Journal:  Oncologist       Date:  2019-11-07

Review 2.  Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors.

Authors:  Lillian Sun; Joshua Arbesman; Melissa Piliang
Journal:  Arch Dermatol Res       Date:  2020-06-09       Impact factor: 3.017

3.  Health-related quality of life measures and immune checkpoint inhibitors: A systematic review.

Authors:  Frances M Walocko; Bao Chau Ly; Mia S White; Suephy C Chen; Howa Yeung
Journal:  J Am Acad Dermatol       Date:  2019-11-01       Impact factor: 11.527

Review 4.  Immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-23       Impact factor: 11.527

5.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Authors:  Gregory S Phillips; Jennifer Wu; Matthew D Hellmann; Michael A Postow; Naiyer A Rizvi; Azael Freites-Martinez; Donald Chan; Stephen Dusza; Robert J Motzer; Jonathan E Rosenberg; Margaret K Callahan; Paul B Chapman; Larisa Geskin; Adriana T Lopez; Vanessa A Reed; Gabriella Fabbrocini; Maria Carmela Annunziata; Oluwaseun Kukoyi; Aliyah Pabani; Chih-Hsun Yang; Wen-Hung Chung; Alina Markova; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2019-06-19       Impact factor: 50.717

Review 6.  Immune-related cutaneous adverse events due to checkpoint inhibitors.

Authors:  Evelyn Wang; Lukas Kraehenbuehl; Kwami Ketosugbo; Jeffrey A Kern; Mario E Lacouture; Donald Y M Leung
Journal:  Ann Allergy Asthma Immunol       Date:  2021-02-17       Impact factor: 6.248

7.  IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.

Authors:  D M Barrios; G S Phillips; A N Geisler; S R Trelles; A Markova; S J Noor; E A Quigley; H C Haliasos; A P Moy; A M Schram; J Bromberg; S A Funt; M H Voss; A Drilon; M D Hellmann; E A Comen; S Narala; A B Patel; M Wetzel; J Y Jung; D Y M Leung; M E Lacouture
Journal:  Ann Oncol       Date:  2021-03-03       Impact factor: 51.769

Review 8.  Balancing Cancer Immunotherapy Efficacy and Toxicity.

Authors:  Douglas B Johnson; Baruch D Jakubovic; Vincent Sibaud; Meghan E Sise
Journal:  J Allergy Clin Immunol Pract       Date:  2020-06-26

Review 9.  Non-dermatological Challenges of Chronic Itch.

Authors:  Andreas E Kremer; Thomas Mettang; Elke Weisshaar
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

Review 10.  Dermatologic conditions in women receiving systemic cancer therapy.

Authors:  Michelle N Ferreira; Julie Y Ramseier; Jonathan S Leventhal
Journal:  Int J Womens Dermatol       Date:  2019-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.